Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 1/2005

01-01-2005 | Original Article

11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET

Authors: Sungeun Kim, June-Key Chung, So-Hyang Im, Jae Min Jeong, Dong Soo Lee, Dong Gyu Kim, Hee Won Jung, Myung Chul Lee

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2005

Login to get access

Abstract

Purpose

The purpose of this study was to compare the prognostic value of 11C-methionine (MET) and 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in glioma patients.

Methods

The study population comprised 47 patients with gliomas (19 glioblastoma, 28 others). Pretreatment magnetic resonance imaging, MET PET and FDG PET were performed within a time interval of 2 weeks in all patients. The uptake ratio and standard uptake values were calculated. Univariate and multivariate analyses were done to determine significant prognostic factors. Ki-67 index was measured by immunohistochemical staining, and compared with FDG and MET uptake in glioma.

Results

Among the several clinicopathological prognostic factors, tumour pathology (glioblastoma or not), age (≥60 or <60 years), Karnofsky performance status (KPS) (≥70 or <70) and MET PET (higher uptake or not compared with normal cortex) were found to be significant predictors by univariate analysis. In multivariate analysis, tumour pathology, KPS and MET PET were identified as significant independent predictors. The Ki-67 proliferation index was significantly correlated with MET uptake (r=0.64), but not with FDG uptake.

Conclusion

Compared with FDG PET in glioma, MET PET was an independent significant prognostic factor and MET uptake was correlated with cellular proliferation. MET PET may be a useful biological prognostic marker in glioma patients.
Literature
1.
Winger MJ, Madonald DR, Cairncross JG. Supratentorial anaplastic glioma in adults. J Neurosurg 1989;71:487–93.PubMed
2.
Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95:190–8.
3.
Russell D, Rubinstein L. Tumours of central neuroepithelial origin. In: Rubinstein LJ, editor. Pathology of tumours of the central nervous system. Baltimore: Williams & Wilkins; 1989. p. 83–350.
4.
Bampoe JO, Bauman G, Cairncross JG. Adult low-grade glioma: natural history, prognostic factors, and timing of treatment. In: Rock JP, Rosenblum ML, Shaw EG, Cairncross JG, editors. The practical management of low-grade primary brain tumors. Philadelphia: Williams & Wilkins; 1999. p. 135–48.
5.
Olson JD, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 2000;54:1442–8.PubMed
6.
Piepmeier J, Christopher S, Spencer D, et al. Variations in the natural history and survival of patients with supratentorial low-grade astrocytoma. Neurosurgery 1996;38:872–9.PubMed
7.
Lote K, Egeland T, Hager B, et al. Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. J Clin Oncol 1997;15:3129–40.PubMed
8.
Alavi JB, Alavi A, Chawluk J, et al. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 1988;62:1074–8.PubMed
9.
De Witte O, Lefranc F, Levivier M, Salmon I, Brotchi J, Goldman S. FDG-PET as a prognostic factor in high-grade astrocytoma. J Neurooncol 2000;49:157–63.CrossRefPubMed
10.
Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32:623–48.PubMed
11.
Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972–80.PubMed
12.
Schober O, Duden C, Meyer GJ, Muller JA, Hundeshagen H. Non-selective transport of [11C-methyl]-l-and d-methionine into a malignant glioma. Eur J Nucl Med 1987;13:103–5.PubMed
13.
Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998;39:778–85.PubMed
14.
Derlon JM, Bourdet C, Bustany P, Chatel M, Theron J, Darcel F, Syrota A. [11C]l-methionine uptake in gliomas. Neurosurgery 1989;25:720–8.PubMed
15.
Chung JK, Kim YK, Kim SK, et al. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging 2002;29:176–82.CrossRefPubMed
16.
De Witte O, Goldberg I, Wilker D, et al. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 2001;95:746–50.PubMed
17.
Ishiwata K, Ido T, Vaalburg W. Increased amounts of d-enantiomer dependent on alkaline concentration in the synthesis of l-[methyl-11C]methionine. Appl Radiat Isot 1988;39:310–4.
18.
Vecht C, Acesaat CJJ, Van Putten WLJ, et al. The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients. J Neurol Neurosurg Psychiatry 1990;53:466–71.
19.
Albert FK, Forsting M, Sator K, et al. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth prognosis. Neurosurgery 1994;34(6):45–61.
20.
Walker MD, Green SB, Byar DP, et al. Randomized comparison of radiotherapy and nitrosureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303(7):1323–9.PubMed
21.
Levin VA, Wara WM, Davis RL, et al. Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J Neurosurg 1985;63:218–23.PubMed
22.
Langen KJ, Muhlensiepen H, Holschbach M, Hautzel H, Jansen P, Coenen HH. Transport mechanisms of 3-[123I]iodo-alpha-methyl-l-tyrosine in a human glioma cell line: comparison with [3H]methyl-l-methionine. J Nucl Med 2000;41:1250–5.PubMed
23.
Delbeke D, Meyerowitz C, Lapidus RL, et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 1995;195:47–52.PubMed
24.
Jeong HJ, Min JJ, Park JM, et al. Determination of the prognostic value of [18F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun 2002;23:865–70.CrossRefPubMed
25.
Oshida M, Uno K, Suzuki M, et al. Predicting the prognosis of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-d-glucose. Cancer 1998;82:2227–34.CrossRefPubMed
26.
Minn H, Lapela M, Klemi PJ, et al. Prediction of survival with fluorine-18-fluorodeoxyglucose and PET in head and neck cancer. J Nucl Med 1997;38:1907–11.PubMed
27.
Miyazawa H, Arai T, Ito M, Hara T. PET imaging of non-small-cell lung carcinoma with carbon-11-methionine: relationship between radioactivity uptake and flow-cytometric parameters. J Nucl Med 1993;34:1886–91.PubMed
28.
Sato N, Suzuki M, Kuwata N, Kuroda K, Wada T, Beppu T, et al. Evaluation of the malignancy of glioma using 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining. Neurosurg Rev 1999;22(4):210–4.CrossRefPubMed
29.
Kubota K. From tumor biology to clinical PET: a review of positron emission tomography (PET) in oncology. Ann Nucl Med 2001;15:471–86.PubMed
Metadata
Title
11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET
Authors
Sungeun Kim
June-Key Chung
So-Hyang Im
Jae Min Jeong
Dong Soo Lee
Dong Gyu Kim
Hee Won Jung
Myung Chul Lee
Publication date
01-01-2005
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2005
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-004-1598-6

Other articles of this Issue 1/2005

European Journal of Nuclear Medicine and Molecular Imaging 1/2005 Go to the issue

Image of the Month

Sestamibi scintigraphy reveals adenocarcinoma of the lung

Controversies-Against

Pulmonary embolism: is multislice CT the method of choice?

Original Articles

Validation of anatomical standardization of FDG PET images of normal brain: comparison of SPM and NEUROSTAT

Original Article

Myocardial metabolism of 123I-BMIPP under low-dose dobutamine infusion: implications for clinical SPECT imaging of ischemic heart disease

Original Article

Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value

Editorial

Imaging of unstable atherosclerotic lesions